Q-omics provides the consensus-scored UBQLN4 profile across patient tissues and cancer cell-line models. UBQLN4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, UBQLN4 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, UBQLN4 RNA expression shows 22,172 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, COAD, and LSCC as cancer lineages where UBQLN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBQLN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBQLN4 survival associations across molecular data types. UBQLN4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBQLN4 RNA expression–survival associations across cancer types. High UBQLN4 expression shows unfavorable associations in MESO, ACC, LIHC, KIRP and KICH, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for UBQLN4 RNA expression.
This table summarizes UBQLN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBQLN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBQLN4 shows higher tumor expression in COAD, KIRP, HNSC, LIHC, LUAD and BLCA. The COAD box plot shows higher UBQLN4 RNA expression in tumor versus normal tissue (log2 FC = +1.202, t-test p < 0.001).
This table shows molecular features associated with UBQLN4 in patient tissues and cancer cell lines. In patient samples, UBQLN4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBQLN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
